ERBB2 and breast cancer: Moreover, CTD can induce growth inhibition in triple-negative breast cancer cell lines, MDA-MB-231 [45,53] and MDA-MB-468, which is the most difficult breast cancer type to cure due to resistance to the already established breast cancer therapies, i.e., endocrine therapies and HER-2 targeted therapy [54].